Lundbeck

29,64

DKK

+0,2 %

Mindre end 1K følgere

HLUN B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Investor consensus

+0,2%

-18,39%

-28,58%

-28,27%

-34,1%

-9,96%

-10,72%

-39,98%

+20,49%

Lundbeck er en farmaceutisk virksomhed. Det største fokus findes i forskning om psykiatriske og neurotiske lidelser, som omfatter behandling af depression, skizofreni, Alzheimers og Parkinsons syndrom. Virksomheden driver forskning, udvikling og videre distribution af lægemidler, hvor kunder findes på globalt plan. Virksomheden blev grundlagt i 1915 og har sit hovedkontor med beliggenhed i Valby.

Markedsværdi

29,51 mia. DKK

Aktieomsætning

8,59 mio. DKK

Omsætning

22 mia.

EBIT %

14,86 %

P/E

9,35

Udbytteafkast, %

3,21 %

Finanskalender

14.5

2025

Delårsrapport Q1'25

20.8

2025

Delårsrapport Q2'25

12.11

2025

Delårsrapport Q3'25

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Pressemeddelelse4.4.2025, 07.00

H. Lundbeck A/S: Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting

Pressemeddelelse31.3.2025, 09.00

H. Lundbeck A/S: Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention

Selskabsmeddelelse26.3.2025, 11.28

H. Lundbeck A/S: Lundbeck held its Annual General Meeting on 26 March 2025 at the company's registered office

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Pressemeddelelse13.3.2025, 08.00

H. Lundbeck A/S: Rxulti[®] (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older

Pressemeddelelse10.3.2025, 08.01

H. Lundbeck A/S: Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

Selskabsmeddelelse25.2.2025, 09.00

To the shareholders of H. Lundbeck A/S

Selskabsmeddelelse21.2.2025, 12.27

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Pressemeddelelse12.2.2025, 08.00

H. Lundbeck A/S: Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA

Selskabsmeddelelse5.2.2025, 15.40

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Selskabsmeddelelse5.2.2025, 06.46

H. Lundbeck A/S: Lundbeck Annual Report 2024

Selskabsmeddelelse5.2.2025, 06.23

H. Lundbeck A/S: Lundbeck reached record revenue of DKK 22 billion in 2024 with accelerated growth for strategic brands (+21% CER)

Selskabsmeddelelse4.2.2025, 16.10

H. Lundbeck A/S: Lundbeck announces changes to the Board of Directors

Pressemeddelelse30.1.2025, 08.00

H. Lundbeck A/S: Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies

Selskabsmeddelelse9.1.2025, 13.07

H. Lundbeck A/S: Lundbeck announces FDA plans to host an Advisory Committee meeting on the sNDA for brexpiprazole in combination with sertraline for the treatment of adults with PTSD

Pressemeddelelse5.12.2024, 12.00

H. Lundbeck A/S: Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations

Pressemeddelelse3.12.2024, 07.00

H. Lundbeck A/S: Efficacy of Vyepti highlighted by new clinical trial results in severe migraine

Pressemeddelelse2.12.2024, 14.08

H. Lundbeck A/S: Lundbeck completes acquisition of Longboard

Selskabsmeddelelse28.11.2024, 06.56

H. Lundbeck A/S: Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled

Pressemeddelelse27.11.2024, 07.00

H. Lundbeck A/S: Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy

Selskabsmeddelelse13.11.2024, 06.29

H. Lundbeck A/S: Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.